´ë¿õÀº ¹Ì±¹ »ý¹°ÇÐÀûÁ¦Á¦ ¾÷¼ÒÀÎ Priveterra Acquisition Corp.ÀÇ ÁÖ½Ä 346¸¸3õ318ÁÖ¸¦ ¾à 438¾ï¿ø¿¡ ÃëµæÇÑ´Ù°í 24ÀÏ °ø½ÃÇß´Ù.
ȸ»çÃøÀº ÅõÀÚ¸ñÀû¿¡ ´ëÇØ "º¸Åø¸®´® Åå½Å Á¦Á¦ ‘³ªº¸Å¸’ÀÇ ±Û·Î¹ú Ä¡·á»ç¾÷ ÆÄÆ®³Ê½Ê °ÈÇϱâ À§ÇÑ °Í"À̶ó°í ¹àÇû´Ù.
PriveterraÞä´Â ¹Ì±¹ ¼ÒÀç ¹ÙÀÌ¿Àº¥Ã³ Aeon Biopharma, Inc. (ÀÌÇÏ AeonÞä)¿Í 2022³â 12¿ù 12ÀÏ¿¡ ü°áÇÑ ÇÕº´°è¾à(Business Combination Agreement)¿¡ ÀÇÇØ, ¾ç»çÀÇ º¸ÅëÁÖ½ÄÀ» ±³È¯ÇÏ´Â ¾àÁ¤À» ü°áÇß´Ù.
PriveterraÞä´Â 2023³â 7¿ù 21ÀÏ ¹Ì±¹ ³ª½º´Ú¿¡ ´ëÇÑ »óÀåöȸ ÈÄ ¹Ì±¹ ´º¿åÁõ±Ç°Å·¡¼Ò(New York Securities Exchange)¿¡ 2023³â 7¿ù 24ÀÏ Àç»óÀåÇÒ ¿¹Á¤À̸ç, »óÈ£¸¦ Aeon Biopharma, Inc.·Î º¯°æÇÒ ¿¹Á¤ÀÌ´Ù.
¹Úº´¿ì ±âÀÚ bwpark0918@pharmstock.co.kr
<ÀúÀÛ±ÇÀÚ © ÆʽºÅ¹, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>